A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Phase 3
18+
12 sites in CA, FL, KY +5
About this study
This Phase 3 study is testing Irinotecan in people with pancreatic adenocarcinoma. The primary outcome being measured is Overall Survival (OS).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), oxaliplatin, fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells)
injection (Injection), oral (Oral Capsule)
Primary: Overall Survival (OS)
Secondary: Change from baseline in EORTC QLQ-C30, Change from baseline in EORTC QLQ-PAN26, Change from baseline in EuroQol 5-dimensional 5-level version (EQ-5D-5L), Change from baseline in Patient Global Impression of Change (PGIC)., Change from baseline in Patient Global Impression of Severity PGIS, Number of Participants with Adverse Events (AEs), Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status., Number of Participants with Serious Adverse Events (SAEs)
Oncology